Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximately ~$298,000 on June 26, 2026. The sale represented 46.60% of Kihara's direct holdings and reduced direct ownership to 13,088 shares.

fool.com - 2026-07-11 16:50:01

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-07-09 12:40:49

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. “Carl is a proven global leader with a stro.

businesswire.com - 2026-07-06 09:04:00

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.

zacks.com - 2026-06-29 12:16:06

Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.

seekingalpha.com - 2026-06-29 11:19:58

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-06-29 10:40:42

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) regarding its drug DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in the European Union.

benzinga.com - 2026-06-26 13:47:10

Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.

fool.com - 2026-06-26 12:17:59

Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval of the Rett syndrome drug, Daybu.

investors.com - 2026-06-26 10:24:03

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.

businesswire.com - 2026-06-26 06:49:00

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:36:20

ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company's clinical rationale for remlifanserin in Alzheimer's disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business development priorities.

marketbeat.com - 2026-05-19 10:15:48

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 22:10:54

ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.

marketbeat.com - 2026-05-12 20:25:12

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.

zacks.com - 2026-05-07 12:46:29

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 04:41:24

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago.

zacks.com - 2026-05-06 18:25:47

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and by the initial up.

businesswire.com - 2026-05-06 16:05:00

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and.

businesswire.com - 2026-04-30 16:05:00

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-04-30 12:40:27

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:01:42

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-29 11:01:47

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Tuesday, May 19, 2026 at 9:00 a.m. Eastern Time in New York, NY Live webcasts will be accessible on the company's website, acadia.com, under the investors s.

businesswire.com - 2026-04-28 16:05:00

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults w.

businesswire.com - 2026-04-17 09:05:00

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call.

businesswire.com - 2026-04-15 16:05:00